{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:03:56Z","timestamp":1790841836070,"version":"4.1.0"},"reference-count":33,"publisher":"American Diabetes Association","issue":"7","funder":[{"name":"The Robert and Janice McNair Foundation, Houston, TX"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To assess the safety and efficacy of dual sodium\u2013glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or placebo in a randomized, double-blind trial assessing safety, insulin dose, glycemic control, and other metabolic parameters over 29 days of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>In the sotagliflozin-treated group, the percent reduction from baseline in the primary end point of bolus insulin dose was 32.1% (P = 0.007), accompanied by lower mean daily glucose measured by continuous glucose monitoring (CGM) of 148.8 mg\/dL (8.3 mmol\/L) (P = 0.010) and a reduction of 0.55% (5.9 mmol\/mol) (P = 0.002) in HbA1c compared with the placebo group that showed 6.4% reduction in bolus insulin dose, a mean daily glucose of 170.3 mg\/dL (9.5 mmol\/L), and a decrease of 0.06% (0.65 mmol\/mol) in HbA1c. The percentage of time in target glucose range 70\u2013180 mg\/dL (3.9\u201310.0 mmol\/L) increased from baseline with sotagliflozin compared with placebo, to 68.2% vs. 54.0% (P = 0.003), while the percentage of time in hyperglycemic range &amp;gt;180 mg\/dL (10.0 mmol\/L) decreased from baseline, to 25.0% vs. 40.2% (P = 0.002), for sotagliflozin and placebo, respectively. Body weight decreased (1.7 kg) with sotagliflozin compared with a 0.5 kg gain (P = 0.005) in the placebo group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved glycemic control and the CGM profile with bolus insulin dose reduction, weight loss, and no increased hypoglycemia in type 1 diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc14-2806","type":"journal-article","created":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T00:31:53Z","timestamp":1433637113000},"page":"1181-1188","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":191,"title":["Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes"],"prefix":"10.2337","volume":"38","author":[{"given":"Arthur T.","family":"Sands","sequence":"first","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Zambrowicz","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes and Endocrine Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Bode","sequence":"additional","affiliation":[{"name":"Atlanta Diabetes Associates, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish K.","family":"Garg","sequence":"additional","affiliation":[{"name":"University of Colorado Denver\/Barbara Davis Center for Childhood Diabetes, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Banks","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Heptulla","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Medical Center, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Rendell","sequence":"additional","affiliation":[{"name":"Creighton Diabetes Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Cefalu","sequence":"additional","affiliation":[{"name":"Pennington Biomedical Research Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Strumph","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,6,11]]},"reference":[{"key":"2022031221215643900_B1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031221215643900_B2","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","article-title":"Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry","volume":"98","author":"Weinstock","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221215643900_B3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/pedi.12030","article-title":"Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry","volume":"14","author":"Cengiz","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"2022031221215643900_B4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00125-007-0824-8","article-title":"Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989","volume":"50","author":"Patterson","year":"2007","journal-title":"Diabetologia"},{"key":"2022031221215643900_B5","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJMoa066397","article-title":"Long-term effect of diabetes and its treatment on cognitive function","volume":"356","author":"Jacobson","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031221215643900_B6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2337\/dc07-2029","article-title":"Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults","volume":"31","author":"Feltbower","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031221215643900_B7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00125-005-0082-6","article-title":"Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway","volume":"49","author":"Skrivarhaug","year":"2006","journal-title":"Diabetologia"},{"key":"2022031221215643900_B8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/erp.12.80","article-title":"Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey","volume":"13","author":"Willis","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2022031221215643900_B9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1464-5491.2010.02972.x","article-title":"Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT\/EDIC","volume":"27","author":"Larkin","year":"2010","journal-title":"Diabet Med"},{"key":"2022031221215643900_B10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00431-010-1372-7","article-title":"Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy","volume":"170","author":"\u0141uczy\u0144ski","year":"2011","journal-title":"Eur J Pediatr"},{"key":"2022031221215643900_B11","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4158\/EP.14.7.912","article-title":"Glycemia and cardiovascular disease in type 1 diabetes mellitus","volume":"14","author":"Wajchenberg","year":"2008","journal-title":"Endocr Pract"},{"key":"2022031221215643900_B12","first-page":"453","article-title":"SGLT-2 inhibitors and their potential in the treatment of diabetes","volume":"6","author":"Rosenwasser","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031221215643900_B13","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/dc11-0096","article-title":"Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual \u03b2-cell function","volume":"34","author":"Kielgast","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031221215643900_B14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031221215643900_B15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031221215643900_B16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2022031221215643900_B17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2022031221215643900_B18","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221215643900_B19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/jpet.113.203364","article-title":"LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose","volume":"345","author":"Powell","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031221215643900_B20"},{"key":"2022031221215643900_B21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.112.193045","article-title":"KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models","volume":"342","author":"Shibazaki","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031221215643900_B22","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"2022031221215643900_B23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY(3-36) physiologically inhibits food intake","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature"},{"key":"2022031221215643900_B24"},{"key":"2022031221215643900_B25"},{"key":"2022031221215643900_B26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031221215643900_B27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clinthera.2014.10.026","article-title":"LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion","volume":"37","author":"Zambrowicz","year":"2015","journal-title":"Clin Ther"},{"key":"2022031221215643900_B28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/dia.2010.0090","article-title":"Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm","volume":"13","author":"Baghurst","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"2022031221215643900_B29","volume-title":"National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"2022031221215643900_B30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejpb.2010.04.003","article-title":"Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transporter-mediated D-glucose uptake","volume":"75","author":"Sakuma","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"2022031221215643900_B31","unstructured":"Dobbins RL, Chen L, Liu YJ, et al. Glucose transport via SGLT1 is critical for post-prandial GIP secretion in rats and humans (Abstract). Diabetes 2012;61(Suppl. 1):A475\u2013A476"},{"key":"2022031221215643900_B32","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221215643900_B33","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4158\/EP13065.OR","article-title":"Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus","volume":"19","author":"Kuhadiya","year":"2013","journal-title":"Endocr Pract"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/7\/1181\/624272\/dc142806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/7\/1181\/624272\/dc142806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:34:18Z","timestamp":1647128058000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/7\/1181\/30848\/Sotagliflozin-a-Dual-SGLT1-and-SGLT2-Inhibitor-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,11]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,6,11]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-2806","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,11]]}}}